Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: NervGen Pharma, Janux Therapeutics and More
Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.
Chinese-Language Podcast: ESMO上的中国数据
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
Pharma Past Propels Julie Brown To GSK’s CFO Position
GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.
Executives On The Move: New Roles Filled at Lisata Therapeutics, Roquefort Therapeutics and Voyager Therapeutics
This week's executive changes in the industry include new CEOs at Roquefort Therapeutics, Lisata Therapeutics and Everest Medicines, while Vyriad and RenovoRx get new chief operating officers.
New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
Novo Nordisk Committed To Advancing In Cardiovascular
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
Executives On The Move: Metagenomi, Psilotech Health Solutions and More
Recent executive changes in the industry include C-suite changes at TherapeuticsMD and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Metagenomi and Psilotech Health Solutions.
Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism
The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.
Executives On The Move: Precision Biosciences, Revolution Medicines and More
Recent executive changes in the industry include C-suite changes at Precision Biosciences and Revolution Medicines. Meanwhile, new directors were appointed at Sanofi and Arcutis Biotherapeutics.
From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
Architect Of Keytruda Reflects On A Great Scientific Success Story
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.
Executives On The Move: Altius Healthcare, Aeglea Biosciences And More
Recent executive changes in the industry include C-suite changes at Aeglea Biosciences and I-Mab. Meanwhile, new directors were appointed at Altius Healthcare and Vaxart.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.